Local drug therapy for osteoporosis and osteoporotic fractures

Junxiong ZHU,Chunli SONG

DOI: https://doi.org/10.3969/j.issn.1006-7108.2018.06.020

2018-01-01

Abstract:Although osteoporosis is a systemic metabolic bone disease, its severest outcome is local fragility fracture.Current treatment of osteoporosis is still largely dependent on systemic administration of drugs.However, systemic medications have certain drawbacks such as long treatment duration, high cost, poor compliance and large systemic side effects.The predilection sites for osteoporotic fractures are mostly concentrated in the thoracolumbar vertebra bodies and hips.The rapid development of modern minimally invasive surgery makes it possible for the local treatment of osteoporosis.By local stimulation of bone formation or inhibition of bone resorption, local drug therapy can prevent fractures, accelerate fracture healing and strengthen the stability of implants in destination spots, and thus compensate for the side effects and slow onset of systemic medications.Local treatment works by local injection of drugs or implant surface coatings.At present, a variety of delivery systems are available for efficient loading and sustained release of biologically active drugs.Other than common preclinical drugs such as bisphosphonates, parathyroid hormone (PTH), bone morphogenetic protein (BMP) and statins, those targeting receptor activator of nuclear factor kappa-B (RANK) and the wingless-related integration site (Wnt) signaling pathways are also under study.In brief, local treatment of osteoporosis may provide a new adjuvant treatment strategy.Combined application of systemic and local treatment is the trend of osteoporosis research and treatment.